Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer

Figure 3

Receiver operating characteristic (ROC) curves for major tumor biomarkers of various types of tumors ((a) lung squamous carcinoma, (b) lung adenocarcinoma, (c) colorectal cancer, (d) pancreatic cancer, and (e) cholangiocarcinoma) compared with the evaluation results of response evaluation criteria in solid tumor (RECIST) standards and HPD standard in this study to determine the cut-off values for the occurrence of HPD.

(a)

(b)

(c)

(d)

(e)